In a brief review it is shown that historically drug treatment of Alzheimer’s disease has addressed at first unspecific symptoms. The subsequent therapy with vasodilators reflected the understanding of the nature of the illness at the time. Another intellectual construction was derived from the amine deficiency hypothesis of depression (use of stimulants). The many subsequent efforts in the development of therapeutic progress based on morphological and biochemical deficits have demonstrated that all the simple cause/effect models are inappropriate. New concepts are matter for discussion.


Cerebral Blood Flow Senile Dementia Organic Brain Syndrome Cognitive Infirmity Prog Neuropsychopharmacol Biol Psychiatry 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baltes PB, Willis SL (1982) Plasticity and enhancement of intellectual functioning in old age: Penn State’s adult development and enrichment program (ADEPT). In: Craik FIM, Trehub SE (eds) Aging and cognitive processes. Plenum Press, New York, pp 353–389CrossRefGoogle Scholar
  2. Bartus RT, Dean RL, Beer B (1984) Cholinergic precursor therapy for geriatric cognition: its past, its present and a question of its future. In: Ordy JM, Harmann D, Alfin-Slater RB (eds) Nutrition in gerontology. Raven Press, New York, pp 191–225Google Scholar
  3. Bartus RT, Dean RL, Fisher SK (1986) Cholinergic treatment for age related memory disturbances: dead or barely coming of age. In: Crook T, Bartus R, Ferris St, Gershon S (eds) Treatment development strategies for Alzheimer’s disease. Mark Powley, Connecticut, pp 421–450Google Scholar
  4. Bartus RT, Dean RL, Pontocorvo M, Flicker C (1985) The cholinergic hypothesis — a historical, current perspective and future direction. Ann NY Acad Sci 444: 332–358PubMedCrossRefGoogle Scholar
  5. Bartus RT, Dean RL, Sherman KA, Friedman E, Beer B (1981) Profound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged rats. Neurobiol Aging 2: 105–111PubMedCrossRefGoogle Scholar
  6. Bowen DM (1981) Alzheimer’s disease. In: Davison AN, Thompson RMS (eds) The molecular basis of neuropathology. Edward Arnold, London, pp 64–69Google Scholar
  7. Bowen DM, Davison AN (1981) The neurochemistry of ageing and senile dementia: In: Matthews WB, Glaser GH (eds) Recent advances in clinical neurology, vol 3. Churchill Livingstone, EdinburghGoogle Scholar
  8. Bowen D, Smith C, White P, Davison AN (1976) Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophics. Brain 99: 459–496PubMedCrossRefGoogle Scholar
  9. Branconnier RJ, Cole JO (1981) Effects of acute administration of trazodon and amitriptylin on cognition, cardiovascular function, and salivation in the normal geriatric subject. J Clin Psychopharmacol 1: 82S - 88SCrossRefGoogle Scholar
  10. Breyer-Pfaff U, Gaertner HJ (1987) Antidepressiva — Pharmakologie, therapeutischer Einsatz and Klinik der Depression. Wissenschaftliche Verlagsanstalt, StuttgartGoogle Scholar
  11. Broks P, Preston GC, Traub M, Poppleton P, Ward C, Stahl SM (1988) Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia 26(5): 685 —700Google Scholar
  12. CGDA (1986) The Committee for “Geriatric diseases and asthenias” at BGA: impaired brain functions in old age. AMI-Hefte, 1. Bundesgesundheitsamt, BerlinGoogle Scholar
  13. Coper H, Schulze G (1987) Charakterisierung and Wirkungsmechanismen von Nootropika. In: Coper H, Heimann H, Kanowski S, Kunkel H (Hrsg) Hirnorganische Psychosyndrome im Alter III. Springer, Berlin Heidelberg New York Tokyo, S 3–10CrossRefGoogle Scholar
  14. Coper H, Herrmann WM (1988) Psychostimulants, analeptics, nootropics. An attempt to differentiate and assess drugs designated for the treatment of impaired brain functions. Pharmacopsychiatry 21: 211–217Google Scholar
  15. Coper H, Jänicke B, Schulze G (1986) Biopsychological research on adaptivity across the life span of animals. In: Baltes PB, Featherman DL, Lerner RM (eds) Life-span development and behavior, vol 7. LEA, New Jersey, pp 207 —232Google Scholar
  16. Crook T, Bartus RT, Ferris ST, Gershon S (1986) Treatment development strategies for Alzheimer’s disease. Mark Powley, ConnecticutGoogle Scholar
  17. Davies P (1985) A critical review of the role of the cholinergic system in human memory and cognition. Ann NY Acad Sci 444: 212–217PubMedCrossRefGoogle Scholar
  18. De Smet Y, Ruberg M, Serdan M, Dubois B, L’Hermitte F Agid Y (1982) Confusion, dementia and anticholinergics in Parkinson’s disease. J Neurol Neurosurg Psychiatry 45: 1161–1164CrossRefGoogle Scholar
  19. Drachman DA, Leavitt J (1974) Human memory and cholinergic system. A relationship to aging? Arch Neurol 30: 113–121PubMedCrossRefGoogle Scholar
  20. Drachmann DA (1977) Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 27: 783–790CrossRefGoogle Scholar
  21. Duara R, Grady C, Haxby J, Ingar D, Sokoloff L, Margolin RH, Mauring RG, Cutler NR, Rapoport SH (1984) Human brain glucose utilization and cognitive function in relation to age. Ann Neurol 16: 702–713CrossRefGoogle Scholar
  22. Ferris SH, Reisberg B, Crook T (1982) Pharmacologic treatment of senile dementia: choline, L-dopa, piracetam, and choline plus piracetam. In: Corkin S (ed) Alzheimer’s disease: a report of progress. Raven Press, New York, pp 475–481Google Scholar
  23. Flood JF, Cherken A (1988) Effect of acute arecoline, tacrine and arecoline + tacrine post-training administration on retention in old mice. Neurobiol Aging 9: 5–8PubMedCrossRefGoogle Scholar
  24. Ghoneim MM, Mewaldt SP (1975) Effects of diazepam and scopolamine on storage, retrieval and organizational processes in memory. Psychopharmacologia 44: 257–262PubMedCrossRefGoogle Scholar
  25. Giurgea CE (1972) Vers une pharmacologie de l’activité intégrative du cerveau. Tentative du concept nootrope en psychopharmacologie. Actual Pharmacol 25: 115–157Google Scholar
  26. Hock FJ (1987) Drug influences on learning and memory in aged animals and humans. In: Mendlewicz J, Pull, Janke W, Kunkel H (eds) Biological psychology/pharmacopsychology. Karger, Basel, pp 145–160Google Scholar
  27. Hollander E, Mohs RC, Davis KL (1986) Cholinergic approaches to the treatment of Alzheimer’s disease. Br Med Bull 42: 97–100PubMedGoogle Scholar
  28. Hollister LE (1986) Summary and conclusions. In: Crook Th, Bartus RT, Ferris St, Gershon S (eds) Treatment development strategies for Alzheimer’s disease. Mark Powley, Connecticut, pp 671–677Google Scholar
  29. Hollister LE (1986) Drug therapy of Alzheimer’s disease: realistic or not? Prog Neuropsychopharmacol Biol Psychiatry 10: 439–446PubMedCrossRefGoogle Scholar
  30. Hoyer S (1986) Senile dementia and Alzheimer’s disease. Brain blood flow and metabolism. Prog Neuropsychopharmacol Biol Psychiatry 10: 447–478PubMedCrossRefGoogle Scholar
  31. Jacobsen A (1958) The use of Ritalin in psychotherapy of depression of the aged. Psychiatr Q 32: 475–483Google Scholar
  32. Kalinowsky LB, Hippius H (1969) Pharmacological, convulsive and other somatic treatments in psychiatry. Grune and Stratton, New YorkGoogle Scholar
  33. Kopelman MD, Lishman WA (1986) Pharmacological treatments of dementia (non cholinergic). Br Med Bull 42: 101–105PubMedGoogle Scholar
  34. Kraepelin E (1910) Das senile and präsenile Irresein; in Psychiatrie. Ein Lehrbuch für Studierende and Ärzte. Verlag Johann Ambrosius Barth, LeipzigGoogle Scholar
  35. Lassen NA (1959) Cerebral blood flow and oxygen consumption in man. Physiol Rev 39: 183–238PubMedGoogle Scholar
  36. Loew DM, Singer JM (1983) Stimulants and senility. In Cresse I (ed) Neuro-chemical behavioral and clinical perspectives. Raven Press, New York, pp 237–268Google Scholar
  37. Mash DC, Flynn DD, Potter LT (1985) Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer’s disease and experimental cholinergic denervation. Science 228: 1115–1117PubMedCrossRefGoogle Scholar
  38. Mohs RC, Davis BM, Greenwald BS, Mathé AA, Johns CA, Horvath ThB, Davis KL (1985) Clinical studies of the cholinergic deficit in Alzheimer’s disease. II. Psychopharmacologic studies. Am Geriatr Soc 33: 749–757Google Scholar
  39. Narang PK, Cutler NR (1986) Pharmacotherapy in Alzheimer’s disease: basis and rationale. Prog Neuropsychopharmacol Biol Psychiatry 10: 519–531PubMedCrossRefGoogle Scholar
  40. Obrist WD (1979) Cerebral circulatory changes in normal aging and dementia. In: Hoffmeister F Müller D (eds) Brain function in old age. Springer, Berlin Heidelberg New York, pp 278–287CrossRefGoogle Scholar
  41. Parnetti L, Ciuffetti G, Mercuri M, Senin U (1985) Haemorheological pattern in initial mental deterioration: results of a long-term study using piracetam and pentoxifylline. Arch Gerontol Geriatr 4: 141–155PubMedCrossRefGoogle Scholar
  42. Perlick D, Stastny P, Katz I, Mayer M, Mattis St (1986) Memory deficits and anticholinergic levels in chronic schizophrenia. Am J Psychiatry 143: 230–232PubMedGoogle Scholar
  43. Pilch H, Müller WE (1988) Piracetam elevates muscarinic chclinergic receptor density in the frontal cortex of aged but not of young mice. Psychopharmacology 94: 74–78PubMedCrossRefGoogle Scholar
  44. Plotkin DA, Jarvik LF (1985) Cholinergic dysfunction in Alzheimer disease: cause or effect? In: van Ree JM, Matthysse S (eds) Prog Brain Res 65: 91–103CrossRefGoogle Scholar
  45. Rogers RL, Meyer JS, Mortel KF, Mahurin RK, Judd BW (1986) Decreased cerebral blood flow precedes multi-infarct dementia, but follows senile dementia of Alzheimer type. Neurology 36: 1–6PubMedCrossRefGoogle Scholar
  46. Sadeh M, Braham J, Modau M (1982) Effects of anticholinergic drugs on memory in Parkinson’s disease. Arch Neurol 39: 666–667PubMedCrossRefGoogle Scholar
  47. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A (1986) Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer-type. N Engl J Med 315: 1241–1245Google Scholar
  48. Szelies B, Herholz K, Pawlik G (1986) Zerebraler Glukosestoffwechsel bei präseniler Demenz vom Alzheimer Typ — Verlaufskontrolle unter Therapie mit muskarinergem Cholinagonisten. Fortschr Neurol Psychiatr 54: 364–373PubMedCrossRefGoogle Scholar
  49. Tachibana H, Meyer JS, Kitagawa Y, Rogers RL, Okayasu H, Mortel KF (1984) Effects of aging on cerebral blood flow in dementia. J Am Geriatr Soc 32: 114–120PubMedGoogle Scholar
  50. Tomlinson BE, Blessed G, Roth M (1970) Observation on the brains of demented old people. J Neurol Sci 11: 205–242PubMedCrossRefGoogle Scholar
  51. Yesavage JA, Tinkelenberg JR, Berger PA, Hollister LE (1979) Vasodilators in senile dementia: a review of the literature. Arch Gen Psychiatry 36: 220–223PubMedCrossRefGoogle Scholar
  52. Yoshikawa M, Hirai S, Aizawa T, Kuroiwa Y, Goto F, Sotue I, Idia M, Toyokura Y, Yamamura H, Iwasaki Y (1983) A dose response study with dihydroergotoxine mesylate in cerebrovascular disease. J Am Geriatr Soc 31: 1–7PubMedGoogle Scholar
  53. Zornetzer StF (1986) The noradrenergic locus coeruleus and senescent memory dysfunction. In: Crook T, Bartus R, Ferris St, Gershon S (eds) Treatment development strategies for Alzheimer’s disease. Mark Powley, Connecticut, pp 337–359Google Scholar

Copyright information

© Springer-Verlag Wien 1990

Authors and Affiliations

  • H. Coper
    • 1
  1. 1.Department of NeuropsychopharmacologyFree University BerlinGermany

Personalised recommendations